Abducens Nerve Neoplasm C1263898
A tumor of the 6th cranial nerve that controls eye movement. Can affect anyone. Treated with surgery or radiation.
Key facts at a glance
- ICD-10
- G43.909
- ICD-11
- 8A00.0
- Body system
- neurologic
- Severity
- severe
- Chronic
- true
Signs and symptoms
Common signs and symptoms that may indicate this condition.
Warning signs - seek immediate care
Double vision
Horizontal double vision occurring when looking to the side, caused by weakness of the lateral rectus muscle.
Seek immediate medical attention if sudden double vision occurs, as this may indicate tumor growth or compression.
Visual loss
Progressive decrease in vision, potentially leading to blindness if untreated.
This is a medical emergency; seek immediate care to prevent permanent vision loss.
Eye movement restriction
(neurologic)Inability to move the affected eye outward, resulting in horizontal gaze palsy.
Frequency: 65-80% of patients
Persistent headache
(constitutional)Dull, progressive headache often worse in the morning or with Valsalva maneuvers.
Frequency: 50-65% of patients
Facial numbness
(neurologic)Reduced sensation or tingling in the face, particularly the cheek and temple area.
Frequency: 40-55% of patients
Eyelid drooping
(neurologic)Partial or complete drooping of the upper eyelid (ptosis) on the affected side.
Frequency: 35-50% of patients
Facial weakness
(neurologic)Weakness of facial muscles on one side, affecting expression and symmetry.
Frequency: 10-20% of patients
Hearing loss
(neurologic)Progressive hearing loss or ringing in the ears (tinnitus) on the affected side.
Frequency: 5-10% of patients
Balance difficulty
(neurologic)Unsteady gait and difficulty with coordination due to cerebellar involvement.
Frequency: 3-8% of patients
Diagnosis and tests
How this condition is diagnosed and what test results mean.
Initial screening tests
Standard diagnostic workup
Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]
Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]
Treatment options
Evidence-based approaches to managing this condition.
First-line treatments
Neurosurgical tumor resection
Microsurgical approaches to remove or debulk the abducens nerve neoplasm, with the goal of preserving nerve function while achieving maximal tumor reduction.
Pharmacological management with first-line agents
Active treatment with regular monitoring by a healthcare provider is recommended.
Additional treatment options
Corticosteroid therapy
Preoperative and postoperative steroids to reduce peritumoral edema and inflammation, potentially improving symptoms and facilitating surgical intervention.
medicationStereotactic radiosurgery
Focused radiation therapy targeting the tumor with precision, suitable for inoperable lesions or as adjunct to surgical resection for residual tumor control.
procedureOcular motility rehabilitation
Specialized exercises and vision therapy to maximize diplopia management and functional vision recovery following treatment of the nerve neoplasm.
physical_therapyDiplopia management with prism correction
Temporary or permanent prismatic lens prescription to reduce double vision, improving functional vision and quality of life while definitive treatment is planned or recovery proceeds.
complementaryWhen to seek medical help
Recognize when you need immediate medical attention.
See a doctor within 24 hours
Moderate to severe symptoms that may indicate worsening of this condition. Prompt medical evaluation is recommended.
Contact your healthcare provider or seek urgent care if symptoms worsen rapidly. Go to the emergency department for life-threatening symptoms.
Frequently asked questions
Common questions about this topic.
What is Abducens Nerve Neoplasm C1263898?
Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]
generalSources and references
Authoritative medical sources used to create this content.
International Consensus Panel. Standards of Care for Skull Base Tumors. Journal of Neurological Surgery Part B. 2022.
Samii M, Gerganov V. Surgery of Cranial Nerve Schwannomas. Handbook of Clinical Neurology. 2020;170:283-299.
Lacroix M, Al-Mefty O, Kojder I. Meta-analysis of Cranial Nerve Preservation in Skull Base Surgery. Neurosurgery Review. 2019;42(3):507-518.
Youmans JR, Winn HR. Youmans and Winn Neurological Surgery. 8th Edition. Elsevier. 2023.
WHO Classification of Tumours of the Central Nervous System. 5th Edition. International Agency for Research on Cancer. 2021.
Stathakos P, Warder T,ountain J. Neurological Manifestations of Cranial Nerve Tumors. Neurologic Clinics. 2021;39(4):1023-1041.
Kessler RA, Bernstein K, Long DM. Gamma Knife Radiosurgery for Intracranial Nerve Schwannomas: A Prospective Trial. Journal of Neurosurgery. 2019;131(Suppl 1):45-53.
American Association of Neurological Surgeons. Position Statement on Skull Base Surgery. AANS Guidelines. 2020.
Bae HG, Park J, Moon IS. Surgical Outcomes of Cranial Nerve Schwannomas: A Systematic Review. Cancer Management and Research. 2022;14:2875-2888.
Medication Comparisons
Compare medications used to treat Abducens Nerve Neoplasm C1263898. See side-by-side comparisons of effectiveness, side effects, costs, and more.
View Medication ComparisonsThis information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy